Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Jan 4, 2013

NEW YORK (GenomeWeb News) – Nanosphere said in recent filings with the US Securities and Exchange Commission that Winton Gibbons will resign from his role as senior VP of business development at the end of April, and that Bill Moffitt will continue to serve as president and CEO under a new agreement that runs through 2013. The agreement provides Moffitt with a base salary of $458,000 with a possible bonus of up to $275,000. Nanosphere said it has no plans to refill Gibbons' position when he departs.

Carl Woese, a microbiology researcher and professor at the University of Illinois at Urbana-Champaign's Institute for Genomic Biology, died recently at the age of 84, the university said this week.

Woese was best known for his research which showed that Archaea are as distinct from bacteria as plants and animals are, leading to the acceptance of these microbes as a third core branch of the tree of life. He was a recipient of the John D. and Catherine T. MacArthur Foundation “genius” award and the National Medal of Science.

SeraCare Life Sciences has added five new executives as part of its move to restructure itself into three business units – IVD Research, IVD Processing, and Clinical Laboratory – to streamline its business processes.

The company has named Russell Garlick to be CSO. Garlick was a co-founder of Life Sciences Group, CEO and CTO of Protein Forest, and worked in R&D at PerkinElmer Life Sciences and DuPont NEN Life Sciences. Cheri Walker joins the firm as chief commercial officer, and she will head the IVD Research and Clinical Laboratory units. Walker has served as a consultant for private equity firms and she held senior corporate development and marketing positions at Charles River Laboratories, Qiagen, and Invitrogen. Ann McCormick will be the company's COO. She co-founded and managed SeraMatrix and worked at Invitrogen and Beckman. Joe Kozma, a former executive at Serologicals and Millipore, has joined the company as president of IVD Process Solutions. And Lisa Alexander has been named SeraCare's VP of quality and regulatory affairs. She previously held similar positions in quality and regulatory affairs at Xcellerex, Millipore, Amgen, GTC Biotherapeutics, and BioReliance.

Kurt Schmidt has been appointed CEO of Skyline Diagnostics. Schmidt joins Skyline from Agendia, where he had served as chief financial officer since 2009. Before Agendia, Schmidt was operations director at B2eMarkets and he was director of finance and operations at LA Gear Europe. In connection with Schmidt's appointment, Skyline's former CEO Henk Viëtor has been appointed to the supervisory board of the Rotterdam, Netherlands-based company.

Omicia has appointed Mike Aicher to be company CEO and a member of its board of directors. Aicher formerly was CEO of the National Genetics Institute, which he co-founded in 1991 and which became a subsidiary of LabCorp. Aicher also led LabCorp's Western Division, and he held a number of positions at Central Diagnostics Laboratory.

Predictive Biosciences has named Pierre Cassigneul to be its new CEO, replacing Marc Schneebaum, who will return to his post as COO. Cassigneul formerly was president, CEO, and vice chairman of the board at XDx, and he previously held management roles at Abbott Laboratories, Becton Dickinson, Bayer Diagnostics, and Ortho Diagnostic Systems. He also has served on the board of the Personalized Medicine Coalition.

Interleukin Genetics has appointed Scott Snyder to be chief marketing officer. He will head the launch of the company's genetic risk panel for guiding dental care. Snyder formerly was VP of marketing and GM at Bausch and Lomb, and he worked in marketing leadership roles at Johnson and Johnson.

MetaMark Genetics said this week that Lynda Chin, the company's scientific co-founder, has resigned from her seat on the firm's board of directors.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.